secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2023-03-17T23:59:59+00:00
Accession:  0001867096-23-000037
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma replaces KPMG with Ernst & Young as independent auditor
-----------------------------------------------------------------------

- Audit committee dismissed KPMG as independent registered public accounting firm on March 13, 2023.
- KPMG's reports for FY2022 and FY2021 had no adverse opinion except for a lease accounting change.
- No disagreements or reportable events occurred during the audit periods or interim period through March 13, 2023.
- Ernst & Young engaged as new independent auditor for the fiscal year ending December 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000037/0001867096-23-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000037/xers-20230313.htm
  HTML page:      https://secwatch.observer/filing/0001867096-23-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer